Amlodipine/folic acid - Shenzhen Ausa Pharmed

Drug Profile

Amlodipine/folic acid - Shenzhen Ausa Pharmed

Alternative Names: Amlodipine-FA tablet; Folic acid/amlodipine

Latest Information Update: 25 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shenzhen Ausa Pharmed
  • Class Antianaemics; Antihypertensives; Dihydropyridines; Pterins; Small molecules; Vitamins
  • Mechanism of Action Calcium channel antagonists; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Essential hypertension

Most Recent Events

  • 24 Feb 2016 No development reported - Phase-II/III for Essential hypertension (Treatment-experienced) in China (PO)
  • 24 Feb 2016 No development reported - Phase-II/III for Essential hypertension in China (PO)
  • 30 Sep 2013 Phase-II/III clinical trials in Essential hypertension (treatment-experienced) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top